Table 3.

Pooled relative risk of all grade and high grade irAEs for combination vs nivolumab

All grade irAEs	No. of trials	Pooled RR (95% CI)	Pooled RR	p Value	High grade irAEs	No. of trials	Pooled RR (95% CI)	Pooled RR	p Value
Total incidence	2	1.067–1.254	1.157	0.000	Total incidence	2	1.337–2.089	1.672	0.000
Discontinuation	2	1.062–1.975	1.448	0.019	Discontinuation	1	1.133–2.656	1.735	0.011
Fatigue	2	0.550–1.660	0.956	0.872	Fatigue	2	0.720–11.245	2.845	0.136
Pruritis	2	1.320–2.736	1.900	0.001	Pruritis	2	0.245–91.337	4.731	0.304
Rash	2	0.508–2.391	1.102	0.806	Rash	2	0.491–4.239	1.442	0.506
Hyperthyroidism	2	0.947–13.480	3.573	0.060	Hyperthyroidism	1	0.188–111.215	4.577	0.350
Hypothyroidism	2	1.170–2.828	1.819	0.008	Hypothyroidism	1	0.124–14.921	1.358	0.803
Nausea	2	1.066–2.482	1.626	0.024	Nausea	2	0.323–12.855	2.037	0.449
Vomiting	2	0.877–3.123	1.655	0.120	Vomiting	2	0.232–10.670	1.573	0.643
Decreased appetite	1	1.282–3.064	1.982	0.002	Decreased appetite	1	0.246–91.812	4.156	0.302
Constipation	1	1.069–6.332	2.602	0.035	Constipation	1	–	–	–
Diarrhea	2	1.092–2.037	1.491	0.012	Diarrhea	2	0.514–5.392	1.664	0.396
Pneumomitis	1	0.353–5.161	1.351	0.660	Pneumomitis	1	0.217–18.948	2.026	0.536